Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04020718 · ClinicalTrials.gov registry record · Phase 4

Engagement With an Adaptive Mobile Health Smoking Cessation Intervention

A Phase 4 study of Tobacco Use Cessation, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
35
Enrollment target
1
Study location

NCT04020718: Completed Phase 4 study of Tobacco Use Cessation, sponsored by Massachusetts General Hospital.

NCT04020718 is a Phase 4 study of Tobacco Use Cessation that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 884-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04020718, a Phase 4 study of Tobacco Use Cessation, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

This is a pilot sequential multiple assignment trial (SMART) to understand the optimal timing to assess response to our smoking cessation text message intervention and to measure how adding medications alone compares to adding medications and telephone coaching for those who continue to smoke. This study aims to assess the feasibility of a SMART of a proactively offered text message intervention for smokers in primary care that compares early (4 weeks) versus late (8 weeks) assessment of treatment response and the addition of nicotine replacement therapy (NRT) alone or with telephone coaching for non-responders.

Primary Outcome

7-day point prevalence abstinence (0, abstinent; 1, smoking), measured as "Have you smoked cigarettes, even a puff, in the past seven days?"

Conditions Studied

Interventions

  • BEHAVIORAL Brief telephone advice plus tailored text messages
  • DRUG Mailed nicotine replacement therapy
  • BEHAVIORAL Proactive telephone coaching

Study Locations (1)

Massachusetts

  • Massacusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2020-01-31
Est. Completion 2020-11-30
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

What the finished NCT04020718 record still lists

NCT04020718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 884-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 3 interventions - of which Brief telephone advice plus tailored text messages is the first listed.

NCT04020718 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04020718 about?

NCT04020718 is a clinical study titled "Engagement With an Adaptive Mobile Health Smoking Cessation Intervention". This is a pilot sequential multiple assignment trial (SMART) to understand the optimal timing to assess response to our smoking cessation text message intervention and to measure how adding medications alone compares to adding medications and telephone coaching for those who continue to smoke. This ...

What is the current status of trial NCT04020718?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2020-01-31. Estimated completion is 2020-11-30.

What conditions does trial NCT04020718 study?

This clinical trial studies the following conditions: Tobacco Use Cessation.

What interventions are being tested in trial NCT04020718?

The interventions under investigation include: Brief telephone advice plus tailored text messages (BEHAVIORAL), Mailed nicotine replacement therapy (DRUG), Proactive telephone coaching (BEHAVIORAL).

Who is sponsoring clinical trial NCT04020718?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04020718 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04020718's enrollment target sits among peer trials

35 34th of 36 higher than 2 of 36 other Tobacco Use Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04020718, the US trial registry maintained by the National Library of Medicine. NCT04020718 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.